Metastatic Disease in Thyroid Gland

Metastatic involvement of the thyroid gland is an uncommon but clinically significant phenomenon, occurring most frequently from primary malignancies of the kidney, lung, breast, gastrointestinal tract and skin. Despite the thyroid’s rich blood supply, its intrinsic high oxygen and iodine content may confer a degree of resistance to colonisation, rendering metastatic nodules relatively rare in routine practice. Patients often present with one or multiple thyroid nodules, sometimes discovered incidentally on imaging or at autopsy, and may be asymptomatic or develop symptoms related to mass effect, such as dysphagia or voice change. Diagnostic evaluation centres on high‐resolution ultrasound followed by tissue sampling, typically via fine‐needle aspiration cytology, enhanced by immunohistochemistry and, increasingly, molecular profiling. Distinction between primary thyroid carcinoma and secondary deposits is crucial, as management differs fundamentally. Solitary metastases limited to the thyroid may warrant surgical resection, potentially offering prolonged survival, whereas disseminated disease requires systemic therapy that may include chemotherapy, targeted agents such as tyrosine kinase inhibitors, and immune checkpoint inhibitors. Overall prognosis is governed by the biology of the primary tumour, the extent of metastatic burden and the timeliness of diagnosis.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Metastatic Disease in Thyroid Gland publication trend

The graph below shows the total number of articles in metastatic disease in thyroid gland across all publications each year (not limited to Nature Index journals).

Technical terms

Fine‐needle aspiration cytology (FNAC): A minimally invasive method to obtain cellular material from a thyroid nodule for microscopic examination.

Immunohistochemistry: A laboratory technique employing antibodies to detect specific antigens in tissue sections, crucial for differentiating primary thyroid cancers from metastatic deposits.

Tyrosine kinase inhibitors: Small-molecule drugs that block aberrant signalling pathways in cancer cells, used as targeted therapy for tumours harbouring specific mutations.

Molecular profiling: Analysis of genetic alterations in tumour cells to identify actionable mutations or fusions that inform personalised treatment strategies.

Solitary metastasis: A single metastatic lesion in the thyroid, often managed surgically with curative intent when the primary cancer is controlled.

References

1. Updates from Our Institutional Experience with Thyroid Nodules Diagnosed as Metastases. Diagnostics (2023).
2. Clinicopathological and Molecular Features of Secondary Cancer (Metastasis) to the Thyroid and Advances in Management. International Journal of Molecular Sciences (2022).
3. Metastases to the Thyroid Gland: What Can We Do?. Cancers (2022).